Jaguar health announces fda conditional approval of canalevia-ca1 (crofelemer), the first and only treatment for chemotherapy-induced diarrhea (cid) in dogs to receive any type of approval from fda

By prescription only, canalevia™-ca1 is a canine-specific formulation of crofelemer, jaguar's novel, oral plant-based product sustainably harvested from the croton lechleri tree san francisco, ca / accesswire / december 21, 2021 / jaguar health, inc. (nasdaq:jagx) today announced it received conditional approval to market canalevia™-ca1 (crofelemer delayed-release tablets), jaguar's oral plant-based prescription drug for the treatment of chemotherapy-induced diarrhea (cid) in dogs. this is the first and only product indicated for the treatment of chemotherapy-induced diarrhea (cid) in dogs to receive any type of approval from fda.
JAGX Ratings Summary
JAGX Quant Ranking